- Cellares announces that Bristol Myers Squibb has joined the Technology Adoption Partnership Program to evaluate automated manufacturing of CAR-T cell therapy on the Cell Shuttle platform
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 /PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to manufacturing cell therapies on a clinical and industrial scale, announced that the global biopharmaceutical company and Cell therapy developer Bristol Myers Squibb (NYSE: BMY) has joined its Technology Adoption Partnership (TAP) program. As part of the agreement, the leading pharmaceutical company will begin a proof-of-concept transfer process for the manufacturing of one of its CAR-T cell therapies, using Cellares' automated manufacturing platform, Cell Shuttle.
Cellares' TAP program is a fast, low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in its portfolio. Bristol Myers Squibb is leveraging this program to evaluate the automated manufacturing process and produce comparability data confirming that Cell Shuttle is a viable, cost-effective, and scalable manufacturing solution for cell therapies. Through its TAP program, Cellares is working with leading cell therapy developers to implement Cell Shuttle as a clinical and commercial stage GMP manufacturing solution at their IDMO Smart Factories.
"We are pleased to welcome Bristol Myers Squibb to the TAP program and look forward to demonstrating the ease and efficiency of transferring one of BMS's cell therapy processes to the Cell Shuttle in the coming months," said Cellares CEO Fabian Gerlinghaus. "By combining built-in automation with a high-performance platform, Cell Shuttle offers unmatched scalability for the cell therapy industry, while improving quality and reducing COGS."
Cellares' flexible manufacturing technology supports autologous and allogeneic cell therapy processes and approximately 90% of cell therapy modalities. Manual processes can be automated and technology transferred to Cellares' Cell Shuttle automated platform in just six months through the company's Technology Adoption Partnership (TAP) program. Under the TAP program, participating cell therapy developers can technology transfer their cell therapy processes to a Cell Shuttle at any stage: during preclinical development, in the clinic, or after regulatory approval. Thanks to automation, standardization and Software Defined Manufacturing (SDM), every subsequent technology transfer is instantaneous to any other Cell Shuttle in any other IDMO smart factory anywhere in the world.
Visit cellares.com/partnering/ to learn more about the TAP program and to request a meeting with a business development representative.
About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass-manufacture the living medicines of the 21st century. The company is developing and operating integrated cell therapy manufacturing technologies to accelerate access to life-saving cell therapies. The company's Cell Shuttle integrates all the technologies required for the entire manufacturing process into a flexible, high-performance platform that offers true end-to-end automation. Cell Shuttles will be deployed in Cellares smart factories around the world to meet the full demand for cell therapies from patients on a global scale. The partnership with Cellares enables academics, biotech and pharmaceutical companies to accelerate drug development and scale up manufacturing, reduce process failure rates, lower manufacturing costs and meet global patient demand.
The company is headquartered in South San Francisco, California, with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is backed by world-class investors and has raised more than $355 million in financing.
For more information about Cellares, visit cellares.com.
Media contact: cellares@consortpartners.com
Logo - https://mma.prnewswire.com/media/1503684/Cellares_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/cellares-anuncia-que-bristol-myers-squibb-se-une-a-su-programa-de-asociacion-para-la-adopcion-de-tecnologia-301911357.html
